Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss of $0.78/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Aurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
March 5, 2020 4:02 PM EST- Cash and cash equivalents totaled approximately $306 million at December 31, 2019 -
- Positive AURORA Phase 3 results with voclosporin enabling an NDA submission for the treatment of lupus nephritis (LN) by the end of the second quarter 2020 -
- Continued build out of a top-tier commercial team, highlighted by the appointment of Max Colao, Chief Commercial Officer, focused on launch activities -
- AUDREY Phase2/3 Dry Eye Study remains on-track with results anticipated during the second half of 2020 -
VICTORIA, British Columbia--(BUSINESS... More
